AnaptysBio seeks partial dismissal in GSK oncology unit dispute over drug royalty [Yahoo! Finance]
AnaptysBio, Inc. (ANAB)
Last anaptysbio, inc. earnings: 3/2 08:45 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.anaptysbio.com/investor-relations
Company Research
Source: Yahoo! Finance
their contract, escalating a ?legal dispute over royalties tied to sales of the cancer drug Jemperli. The dispute centers ?on a 2014 agreement between AnaptysBio and oncology unit Tesaro that gave the latter rights to develop and sell Jemperli, a PD-1 inhibitor approved for certain endometrial cancers. GSK did not immediately respond to Reuters' ?request for a comment ?outside business hours. A trial to resolve claims is scheduled for July 14–17, 2026, and the court is expected ?to hear AnaptysBio's motion by early March. Tesaro filed a lawsuit against AnaptysBio in a Delaware court on November 20, accusing it of breaching the agreement ?and arguing that the alleged breach allowed Tesaro to terminate ?the deal, halve royalty and milestone payments, and secure a permanent license to the drug. AnaptysBio countersued a day later, accusing Tesaro of violating exclusivity terms by participating in trials of rival PD-1 drugs, including Merck's Keytruda, and failing to fully maximi
Show less
Read more
Impact Snapshot
Event Time:
ANAB
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ANAB alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ANAB alerts
High impacting AnaptysBio, Inc. news events
Weekly update
A roundup of the hottest topics
ANAB
News
- What Investors Should Know About a $163K AnaptysBio Insider Sale [Yahoo! Finance]Yahoo! Finance
- What This Insider Trim at AnaptysBio Means for Investors After a 260% Stock Rally [Yahoo! Finance]Yahoo! Finance
- Assessing AnaptysBio (ANAB) Valuation After Strong Recent Share Price Momentum [Yahoo! Finance]Yahoo! Finance
- AnaptysBio (NASDAQ:ANAB) was upgraded by analysts at UBS Group AG to a "strong-buy" rating.MarketBeat
- AnaptysBio Moves to Dismiss GSK's Tesaro Lawsuit Over Jemperli Royalty Dispute [Yahoo! Finance]Yahoo! Finance
ANAB
Earnings
- 11/4/25 - Beat
ANAB
Sec Filings
- 1/9/26 - Form 4
- 1/9/26 - Form 144
- 1/9/26 - Form 4
- ANAB's page on the SEC website